Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens

• Published in: International journal of antimicrobial agents Vol. 18; no. 4; pp. 379 - 382
• Main Authors: Lopez, H, Vilches, V, Scarano, S, Stepanik, D, Smayevsky, J, Lemme, L, Cardeñosa, O, Ambler, J, Sucari, A
• Format: Journal Article
• Language: English
• Published: London Elsevier B.V 01-01-2001; Amsterdam Elsevier; New York, NY
• Subjects: Anti-Infective Agents - pharmacology; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Aza Compounds; Bacteria - drug effects; Biological and medical sciences; Ciprofloxacin - pharmacology; Community acquired respiratory pathogens; Community-Acquired Infections - microbiology; Fluoroquinolones; Haemophilus influenzae - drug effects; Humans; In vitro activity; Levofloxacin; Medical sciences; Microbial Sensitivity Tests; Moraxella (Branhamella) catarrhalis - drug effects; Moxifloxacin; Naphthyridines - pharmacology; Ofloxacin - pharmacology; Pharmacology. Drug treatments; Quinolines; Respiratory Tract Infections - microbiology; Streptococcus pneumoniae - drug effects; Streptococcus pyogenes - drug effects; Community acquired respiratory pathogens; In vitro activity; Moxifloxacin; Respiratory disease; Multicenter study; Neisseriaceae; In vitro; Moraxella; Biological activity; Haemophilus influenzae; Streptococcus pneumoniae; Infection; Pasteurellaceae; Streptococcaceae; Fluoroquinolone derivatives; Minimum inhibitory concentration; Bacteriosis; Bacteria; Micrococcales; Streptococcus pyogenes; Antibacterial agent; Quinolone derivatives
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/S0924-8579(01)00419-8

The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180
Streptococcus pneumoniae, 180
Haemophilus influenzae, 160
Moraxella
catarrhalis and 190
Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections. MIC values for moxifloxacin, trovafloxacin were 0.25/0.25, 0.03/0.03, 0.06/0.03 and 0.125/0.0125 mg/l for
S. pneumoniae,
H. influenzae,
M. catharralis and
S. pyogenes. Based upon the MIC
90 values and the MIC distributions, moxifloxacin and trovafloxacin were the most active of the quinolones tested. They showed enhanced activity against Gram-positive organisms including penicillin non susceptible
S. pneumoniae strains. Moxifloxacin was also highly active against ciprofloxacin-resistant
S. pneumoniae strains.